Literature DB >> 26637275

Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late?

Yu-Xiao Yang1, Anil K Rustgi2.   

Abstract

Metformin offers no survival advantage in patients with metastatic pancreatic cancer. Despite promising experimental evidence suggesting an antitumor effect of metformin, its impact on the survival of advanced pancreatic cancer is likely very limited. Future studies may need to consider its role in early-stage pancreatic cancer. See related article by Reni et al., p. 1076. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26637275      PMCID： PMC4775394          DOI： 10.1158/1078-0432.CCR-15-2494

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  15 in total

Review 1.  Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.

Authors:  Thomas Tang; Jonathan M Lord; Robert J Norman; Ephia Yasmin; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  AMP-activated protein kinase as a drug target.

Authors:  D Grahame Hardie
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

3.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

4.  Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.

Authors:  Sil Kordes; Michael N Pollak; Aeilko H Zwinderman; Ron A Mathôt; Mariëtte J Weterman; Aart Beeker; Cornelis J Punt; Dick J Richel; Johanna W Wilmink
Journal:  Lancet Oncol       Date:  2015-06-08       Impact factor: 41.316

Review 5.  New targeted therapies in pancreatic cancer.

Authors:  Andrada Seicean; Livia Petrusel; Radu Seicean
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

6.  Metformin use is associated with better survival of diabetic patients with pancreatic cancer.

Authors:  Navid Sadeghi; James L Abbruzzese; Sai-Ching J Yeung; Manal Hassan; Donghui Li
Journal:  Clin Cancer Res       Date:  2012-03-31       Impact factor: 12.531

Review 7.  Targeting AMPK: a new therapeutic opportunity in breast cancer.

Authors:  Sirwan M Hadad; Stewart Fleming; Alastair M Thompson
Journal:  Crit Rev Oncol Hematol       Date:  2008-03-14       Impact factor: 6.312

8.  Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

Authors:  R Loomba; G Lutchman; D E Kleiner; M Ricks; J J Feld; B B Borg; A Modi; P Nagabhyru; A E Sumner; T J Liang; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2008-10-09       Impact factor: 8.171

9.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

Review 10.  Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Zheng Wang; Song-Tao Lai; Li Xie; Jian-Dong Zhao; Ning-Yi Ma; Ji Zhu; Zhi-Gang Ren; Guo-Liang Jiang
Journal:  Diabetes Res Clin Pract       Date:  2014-04-18       Impact factor: 5.602
View more
  7 in total

Review 1.  Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis.

Authors:  Judith M Graber; Shou-En Lu; Yong Lin; Grace Lu-Yao; Xiang-Lin Tan
Journal:  Curr Med Chem       Date:  2018       Impact factor: 4.530

Review 2.  Diabetes Mellitus and Obesity as Risk Factors for Pancreatic Cancer.

Authors:  Guido Eibl; Zobeida Cruz-Monserrate; Murray Korc; Maxim S Petrov; Mark O Goodarzi; William E Fisher; Aida Habtezion; Aurelia Lugea; Stephen J Pandol; Phil A Hart; Dana K Andersen
Journal:  J Acad Nutr Diet       Date:  2017-09-12       Impact factor: 4.910

3.  Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer.

Authors:  Marcelo Cerullo; Faiz Gani; Sophia Y Chen; Joe Canner; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2016-06-02       Impact factor: 3.452

4.  The Intricate Metabolism of Pancreatic Cancers.

Authors:  Felipe Camelo; Anne Le
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  No association between metformin use and survival in patients with pancreatic cancer: An observational cohort study.

Authors:  Martine A Frouws; Babs G Sibinga Mulder; Esther Bastiaannet; Marjolein M J Zanders; Myrthe P P van Herk-Sukel; Eleonora M de Leede; Bert A Bonsing; J Sven D Mieog; Cornelis J H Van de Velde; Gerrit-Jan Liefers
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

6.  Glycemic Variability Promotes Both Local Invasion and Metastatic Colonization by Pancreatic Ductal Adenocarcinoma.

Authors:  Ziying Jian; Tao Cheng; Zhiheng Zhang; Susanne Raulefs; Kuangyu Shi; Katja Steiger; Nadja Maeritz; Karin Kleigrewe; Thomas Hofmann; Simone Benitz; Philipp Bruns; Daniel Lamp; Martin Jastroch; Jan Akkan; Carsten Jäger; Peilin Huang; Shuang Nie; Shanshan Shen; Xiaoping Zou; Güralp O Ceyhan; Christoph W Michalski; Helmut Friess; Jörg Kleeff; Bo Kong
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-07-26

7.  The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers: a meta-analysis of randomized controlled trials.

Authors:  Hyeong Su Kim; Jung Han Kim; Hyun Joo Jang; Jin Lee
Journal:  Int J Med Sci       Date:  2020-09-12       Impact factor: 3.738
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.